drugset
Drugs / Fluciclatide
last change Jan 2022 re-read 3 minutes ago

Fluciclatide

also known as (18)F-AH111585 · \[18F\]Fluciclatide · AH111585 · GE [18F]AH111585

Peptide

Investigated by
GE Healthcare · National Cancer Institute (NCI) · BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses) · National Institutes of Health Clinical Center (CC) · Oxford University Hospitals NHS Trust · Quintiles, Inc.
+3 more · University of Oxford · University of Utah · i3 Statprobe

Trials 6

today NCT01788280 · Ph 2 NCT01492192 · Ph 2 NCT01571726 · Ph 2 NCT01176500 · Ph 1/2 NCT00918281 · Ph 2 NCT00565721 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT01176500 Jul 2010 → Nov 2011 cervical cancer, colon carcinoma, lung cancer, renal cell carcinoma National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 25 trials
Phase 2 NCT01788280 Jan 2018 → Jan 2022 glioblastoma University of Utah Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT01492192 May 2013 → Sep 2015 renal cell carcinoma Oxford University Hospitals NHS Trust Terminated No outcome recorded
Phase 2 NCT01571726 Mar 2012 → Apr 2014 monoclonal gammopathy of uncertain significance, smoldering plasma cell myeloma National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 2 NCT00918281 Jun 2009 → Sep 2011 breast cancer, head and neck cancer, high grade astrocytic tumor, lung cancer +2 GE Healthcare Completed No outcome recorded
Phase 2 NCT00565721 Nov 2007 → Oct 2011 head and neck cancer, lung cancer, malignant glioma, melanoma +1 GE Healthcare Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Fluciclatide “Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins...” NCT01492192 ↗
5

“Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab” NCT01788280 ↗

NCT01571726 ↗

NCT00918281 ↗

NCT01176500 ↗

NCT00565721 ↗
Known as (18)F-AH111585 “(18)Fluciclatide (previously known (18)F-AH111585) is a new radiopharmaceutical developed for PET imaging, which targets Alpha(v)Beta(3) receptors.” NCT01571726 ↗
Known as \[18F\]Fluciclatide “\[18F\]Fluciclatide is a new radiopharmaceutical developed for PET imaging” NCT01176500 ↗
Known as AH111585 “Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins...” NCT01492192 ↗
Known as GE [18F]AH111585 “Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab” NCT01788280 ↗
Modality Peptide “18F labelled Cyclic RGD peptide PET agent for injection.” NCT00565721 ↗
Route Intravenous “Following Intravenous Administration” NCT00918281 ↗